David Fredrickson, executive vice president of AstraZeneca's oncology business unit (AstraZeneca) There are still more data to come. While the trial has so far shown a “numerically favorable ...

AstraZeneca is pushing forward with implementing ... significantly reducing mortality rates over the next two decades. David Fredrickson, the Executive Vice-President of the company's Oncology ...

Understand every aspect of the global economy – and know how to make your next move.

The thing that I worry about more than loss of exclusivity is this term that I introduced at the AACR meeting -- loss of relevancy" says Susan Galbraith, EVP of Oncology R&D at AstraZeneca.

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

David Fredrickson-- Executive Vice President ... Alexion and Chief Strategy Officer, AstraZeneca Thank you, Sharon. Can we go to the next slide, please? Rare disease grew 15% to $4.2 billion ...

said AstraZeneca Executive Vice President of Oncology David Fredrickson. The U.S. Food and Drug Administration first approved the drug in 2017 to treat a type of bladder cancer. Imfinzi won ...

AstraZeneca said its breast cancer drug candidate showed positive results in a late stage trial, with improved progression-free survival in patients. The British pharma giant said Wednesday that ...